RPRD2

Across TCGA pan-cancer cohorts, RPRD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPRD2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPRD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPRD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where RPRD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.766	0.920	<.001	38	view →
PDAC	DFS	Tertile	All	0.900	0.624	.003	31	view →
LUAD	OS	Tertile	All	0.934	0.716	.004	15	view →
GBM	OS	Quartile	All	0.605	0.316	.011	9	view →
OV	DFS	Median	All	1.000	0.689	.030	4	view →
LSCC	DFS	Median	III,IV	0.651	0.898	.041	3	view →
CCRCC	DFS	Median	II,III,IV	0.827	0.359	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPRD2–HNSC (OS)

Open the HNSC breakdown →